Skip to main content
. 2014 May 16;31(5):539–560. doi: 10.1007/s12325-014-0120-1

Fig. 2.

Fig. 2

Treatment persistence after 1-year follow-up: the percentage of patients persistent with treatment (a), and the number of days between the index date and date of treatment discontinuation (b). DET-C patients continuing on insulin detemir, DET-S patients switching from insulin glargine to insulin detemir, GLA-C patients continuing on insulin glargine, GLA-S patients switching from insulin detemir to insulin glargine